Physician profile
Ignacio Iturbe
NPI 1972513695
$20,656.61
in general payments reported to CMS, 2019-2025
79 companies · $3,073 in 2025
The $3,073 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $2,395 · 2021: $2,315 · 2022: $3,187 · 2023: $4,219 · 2024: $3,464 · 2025: $3,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,897 · Education: $575 · Long Term Medical Supply Or Device Loan: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,897.15 |
| Education | $575.47 |
| Long Term Medical Supply Or Device Loan | $282.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,456.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,456.03 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,213.36 | 2019-2025 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,186.46 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Pfizer INC. | $928.63 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $748.53 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $697.56 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $653.51 | 2019-2022 | |
| Sobi, INC | $638.27 | 2022-2025 | |
| Seagen INC. | $634.90 | 2019-2023 | Tukysa, Adcetris |
| Astellas Pharma US INC | $592.53 | 2019-2025 | Vyloy, Xospata, Padcev |
| E.R. Squibb & Sons, L.L.C. | $582.09 | 2019-2025 | Opdualag, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $551.06 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Incyte Corporation | $498.79 | 2020-2025 | Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $482.41 | 2019-2025 |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $458.35 | 2019-2025 | |
| Puma Biotechnology, INC. | $386.84 | 2019-2025 | |
| Beigene USA, INC. | $371.83 | 2020-2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $371.08 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Abbvie INC. | $357.96 | 2019-2025 | |
| Epizyme, INC. | $319.42 | 2020-2022 | |
| Kite Pharma, INC. | $312.02 | 2020-2025 | Yescarta |
| Teva Pharmaceuticals USA, INC. | $307.29 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $292.32 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $291.39 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $263.14 | 2019-2024 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $259.96 | 2021-2025 | Ultomiris |
| Dova Pharmaceuticals | $189.56 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $177.99 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Karyopharm Therapeutics INC. | $175.99 | 2020-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.50 | 2019-2025 | Gilotrif |
| Blueprint Medicines Corporation | $169.22 | 2020-2023 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $160.44 | 2019-2024 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $151.73 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $126.00 | 2022-2024 | |
| Array Biopharma INC | $123.03 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Coherus Oncology, INC. | $118.06 | 2020-2022 | |
| Glaxosmithkline, LLC. | $98.02 | 2020-2025 | Ojjaara |
| Myovant Sciences INC. | $94.45 | 2021-2022 | |
| Genzyme Corporation | $89.85 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $88.56 | 2022-2025 | |
| Emd Serono, INC. | $84.11 | 2019-2024 | Bavencio |
| Pharmacosmos Therapeutics INC. | $83.96 | 2023-2024 | Monoferric, Cosela |
| Gilead Sciences, INC. | $78.20 | 2019-2022 | |
| Taiho Oncology, INC. | $75.35 | 2019-2025 | |
| Aurobindo Pharma USA, INC. | $74.20 | 2019 | |
| Mirati Therapeutics, INC. | $68.25 | 2023-2024 | Krazati |
| Eusa Pharma (US) LLC | $59.43 | 2022 | |
| Recordati_rare_diseases_inc. | $57.79 | 2024-2025 | Sylvant |
| Tersera Therapeutics LLC | $51.74 | 2019-2023 | Zoladex |
| Genentech USA, INC. | $51.47 | 2019-2022 | |
| Stemline Therapeutics INC. | $46.43 | 2019-2024 | Orserdu |
| Acrotech Biopharma INC. | $45.78 | 2022-2023 | Beleodaq |
| Mylan Institutional INC. | $43.12 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $39.89 | 2025 | Pyrukynd |
| Clovis Oncology, INC. | $38.48 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $38.31 | 2023-2025 | Rolvedon |
| Caris Mpi, INC. | $29.72 | 2025 | Mi Cancer Seek |
| Deciphera Pharmaceuticals INC. | $27.26 | 2022 | |
| Foundation Medicine, INC. | $27.08 | 2020 | |
| Tempus Ai, INC | $26.55 | 2025 | Xt Cdx |
| Amneal Pharmaceuticals LLC | $25.02 | 2023 | Neulasta, Avastin, Neupogen |
| Genmab U.S., INC. | $24.91 | 2024 | Epkinly |
| Sun Pharmaceutical Industries INC. | $24.75 | 2020 | |
| Verastem, INC. | $24.57 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.93 | 2025 | Danziten |
| Adc Therapeutics America, INC. | $23.36 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.54 | 2024 | |
| Myriad Genetic Laboratories, INC. | $21.26 | 2023 | Myrisk |
| Acadia Pharmaceuticals INC | $21.12 | 2023 | Nuplazid |
| Helsinn Therapeutics (U.S.), INC. | $19.56 | 2019 | |
| Kyowa Kirin, INC. | $18.40 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $17.99 | 2019 | |
| Secura Bio, INC. | $17.27 | 2020 | |
| Shionogi INC | $17.26 | 2020 | |
| Apellis Pharmaceuticals, INC. | $16.74 | 2023 | Empaveli |
| Octapharma USA, INC. | $16.47 | 2024 | Octagam Immune Globulin (Human) |
| Alnylam Pharmaceuticals INC. | $16.42 | 2024 | Amvuttra |
| Telix Pharmaceuticals | $13.03 | 2023 | Illuccix |
Drugs and devices associated with these payments
Keytruda $796Imbruvica $761Doptelet $464Darzalex $415Lenvima $354Lynparza $305Reblozyl $275Libtayo $257Welireg $240Brukinsa $239Tecvayli $234Jakafi $228Kisqali $214Adcetris $210Scemblix $205Erleada $201Nubeqa $191Vitrakvi $185Stivarga $185Ibrance $178Ultomiris $175Elrexfio $169Talvey $165Tukysa $159Imfinzi $157Alunbrig $153Padcev $148Xtandi $148Verzenio $141Vyloy $139Ninlaro $128Fabhalta $125Enhertu $120Pomalyst $119Epkinly $117Jaypirca $115Fotivda $110Opdualag $109Inlyta $108Piqray $108Cabometyx $106Talzenna $105Rybrevant $103Yescarta $101Comirnaty $100Paxlovid $100Orgovyx $96.09Elahere $95.04Onivyde $92.14Keytruda Qlex $92.06Monjuvi $91.53Tevimbra $89.07Nerlynx $83.48Mektovi $81.43Braftovi $81.43Injectafer $78.34Xpovio $75.60Xospata $75.43Krazati $68.25Tibsovo $65.57Opdivo $61.99Xalkori $58.36Lorbrena $58.36Sylvant $57.79Ojjaara $55.80Xofigo $55.13Ayvakit $54.13Bavencio $45.57Tazverik $45.22Promacta $45.15Monoferric $45.00Somatuline Depot $44.90Idhifa $42.48Vonjo $42.02Pyrukynd $39.89Cosela $38.96Rolvedon $38.31Sarclisa $37.96Fruzaqla $36.33Bosulif $35.27Besponsa $35.27Lonsurf $34.42Inqovi $34.42Retevmo $34.23Rezlidhia $32.81Tavalisse $32.81Carvykti $32.62Venclexta $32.10Orserdu $30.55Mi Cancer Seek $29.72Vanflyta $28.62Lutathera $28.43Xt Cdx $26.55Illuccix $26.06Neulasta $25.02Neupogen $25.02Avastin $25.02Tabrecta $24.14Danziten $23.93Gilotrif $23.86
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Iturbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.